AGTC Expands Leadership Team with Appointment of Key
AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 26, 2021 (GLOBE...
Stay updated with breaking news from Otonomy Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 26, 2021 (GLOBE...
AGTC Expands Leadership Team with Appointment of Key Regulatory Leader - read this article along with other careers information, tips and advice on BioSpace
Otonomy: Q1 Earnings Snapshot Last Updated May 11, 2021 at 5:28 pm EDT SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Tuesday reported a loss of $12.2 million in its first quarter. The San Diego-based company said it had a loss of 23 cents per share. The biotechnology company posted revenue of $90,000 in the period. In the final minutes of trading on Tuesday, the company’s shares hit $2.08. A year ago, they were trading at $2.45. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OTIC at h...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update Otonomy, Inc.May 11, 2021 GMT OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway with preclinical proof-of-concept data to be presented at ASGCT meeting; update on program to be provided in mid-2021 Recent financing extend...
Share: OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway with preclinical proof-of-concept data to be presented at ASGCT meeting; update on program to be provided in mid-2021 Recent financing extends cash runway into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicate...